Top Story

FDA approves new treatment for HF

FDA approves new treatment for HF
July 7, 2015

The FDA has approved a first-in-class angiotensin receptor-neprilysin inhibitor for the reduction of CV death and HF-related hospitalization among patients with HF and reduced ejection fraction, according to a press release.

Entresto (Novartis), formerly known as LCZ696, combines the angiotensin receptor blocker valsartan bonded to the neprilysin inhibitor sacubitril. The drug is administered in tablet form twice a day, in place of an ACE inhibitor or angiotensin receptor blocker.

New trial will assess OCT-guided stent implantation

July 7, 2015
St. Jude Medical announced the initiation of the prospective, international ILUMIEN III trial, which will evaluate the use of optical coherence tomography guidance…
Acceleration of cognitive decline occurs after incident stroke In the Journals

Acceleration of cognitive decline occurs after incident stroke

July 7, 2015
Individuals who survive a stroke are more likely to experience severe decline in cognitive function following their stroke, along with accelerated and persistent…
In the Journals

Extended anticoagulation beneficial after pulmonary embolism; stops when treatment ends

July 7, 2015
Patients who experience a first pulmonary embolism may benefit from anticoagulation therapy for up to 2 years after the unprovoked episode, although the benefits of…
In the Journals

Daytime traffic noise exposure may raise mortality risk

July 7, 2015
Long-term exposure to a greater amount of road traffic noise was associated with a small but significant increased risk for mortality and stroke-related hospitalization…
More News Headlines »
CME
Cardiology Case Consults

The Patient with Acute Coronary Syndrome

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with acute coronary syndrome.
More »
Meeting News Coverage Video
VIDEO: Knowledge of supplements and drug interactions essential for HF practitioners

VIDEO: Knowledge of supplements and drug interactions essential for HF practitioners

June 28, 2015
NEW ORLEANS – Joseph Ho, PharmD, clinical pharmacist with Ochsner Baptist Medical Center in New Orleans…
More »
CME
Antiplatelet Agents in ACS Distinguishing Characteristics Safety and Efficacy

Antiplatelet Agents in ACS: Distinguishing Characteristics, Safety, and Efficacy

This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC

It is estimated that in the United States, each year, over 780,000 persons will experience an acute coronary syndrome…
More »
morganatic-roan
morganatic-roan